Table 3.
Outcomes tested for an association with global African ancestry in African Americans from EAGLE BioVU
| Outcome (n) | % or median (± SD) | OR or β (95 % CI or SE) | P-value |
|---|---|---|---|
| Hypertension, baseline (n = 6,422) | 56 % | 0.81 (0.61 – 1.07) | 0.14 |
| Hypertension, lifetime (n = 8,691) | 78 % | 0.81 (0.54 – 1.21) | 0.30 |
| Type 2 diabetes (n = 1,356) | 12 % | 0.75 (0.52 – 1.08) | 0.12 |
| Albumin (g/dL), serum (n = 8,094) | 4.05 (0.51) | 0.02 (0.04) | 0.67 |
| Albumin creatinine ratio (mg/mmol) (n = 1,210) | 14.00 (861.08) | 0.01 (0.17) | 0.95 |
| Albumin (mg/dL), urinary (n = 1,199) | 16.7 (640.2) | 0.04 (0.16) | 0.79 |
| Blood urea nitrogen (mg/dL) (n = 10,111) | 11.00 (13.55) | 0.10 (0.90) | 0.92 |
| Body mass index (kg/m2) (n = 9,247) | 27.25 (7.21) | −0.81 (0.50) | 0.10 |
| Creatinine (mg/dL), serum (n = 10,288) | 0.88 (1.99) | −0.09 (0.13) | 0.50 |
| Creatinine (g/kg/day), urinary (n = 172) | 70.00 (73.89) | −23.54 (38.74) | 0.54 |
| Diastolic blood pressure (mm Hg), baseline (n = 10,025) | 76.00 (15.68) | −0.35 (1.05) | 0.74 |
| Diastolic blood pressure (mm Hg), post-medication (n = 5,653) | 79.00 (10.06) | 0.01 (0.88) | 0.99 |
| Diastolic blood pressure (mm Hg), pre-medication (n = 7,009) | 75.00 (11.28) | −0.37 (0.90) | 0.68 |
| Glucose (mg/dL) (n = 9,918) | 96.00 (34.33) | −0.22 (2.30) | 0.92 |
| Glycated hemoglobin (mg/dL) (n = 2,925) | 6.30 (1.80) | −0.15 (0.22) | 0.49 |
| HDL-C (mg/dL) (n = 5,096) | 50.00 (16.99) | 1.09 (1.60) | 0.49 |
| HDL-c (mg/dL) post-medication (n = 2,097) | 47.75 (16.55) | 2.74 (2.38) | 0.25 |
| HDL-C (mg/dL), pre-medication (n = 4,273) | 51.00 (17.09) | 1.43 (1.73) | 0.41 |
| Heart rate (beats per minute) (n = 783) | 76.00 (11.14) | 2.44 (2.58) | 0.35 |
| Insulin (IU/mL) (n = 343) | 16.90 (74.36) | 11.67 (24.25) | 0.63 |
| LDL-C (mg/dL), regardless of medication status | 99.00 (35.18) | 0.58 (3.31) | 0.86 |
| LDL-C (mg/dL), post-medication | 96.00 (38.90) | −6.00 (5.55) | 0.28 |
| LDL-C (mg/dL), pre-medication | 105.00 (39.70) | 3.52 (4.11) | 0.40 |
| PR Interval (msec) (n = 781) | 159.00 (17.92) | 0.56 (4.16) | 0.89 |
| QRS duration (msec) (n = 837) | 82.00 (8.65) | −7.45 (1.93) | 1.3x10-4 |
| QT interval (msec) (n = 783) | 376.00 (27.84) | −9.66 (6.45) | 0.14 |
| Systolic blood pressure (mm Hg), baseline (n = 10,025) | 125.00 (22.54) | 1.37 (1.50) | 0.36 |
| Systolic blood pressure (mm Hg), post-medication (n = 5,653) | 132.00 (16.03) | −0.30 (1.40) | 0.83 |
| Systolic blood pressure (mm Hg), pre-medication (n = 7,009) | 123.00 (16.38) | −0.06 (1.31) | 0.96 |
| Total cholesterol (mg/dL), regardless of medication status (n = 5,439) | 175.00 (39.48) | −0.35 (3.57) | 0.92 |
| Total cholesterol (mg/dL), post-medication (n = 2,150) | 173.50 (44.22) | −5.40 (6.31) | 0.39 |
| Total cholesterol (mg/dL), pre-medication (n = 4,642) | 181.00 (44.86) | 0.73 (4.38) | 0.86 |
| Triglycerides (mg/dL), regardless of medication status (n = 5,269) | 98.00 (69.46) | −5.70 (6.40) | 0.38 |
| Triglycerides (mg/dL), post-medication (n = 2,115) | 110.00 (74.07) | −15.64 (10.62) | 0.14 |
| Triglycerides (mg/dL), pre-medication (n = 4,445) | 97.00 (79.25) | −1.75 (7.93) | 0.83 |
| Uric acid (mg/dL) (n = 2,465) | 5.40 (2.18) | −0.01 (0.28) | 0.97 |
Tests of association were performed using logistic and linear regression between 36 outcomes and percent African global genetic ancestry among African Americans in EAGLE BioVU (n = 11,166). Descriptive statistics as well as summary statistics of all associations are shown for each outcome tested.
Abbreviations odds ratio (OR), standard deviation (SD), standard error (SE)
Significant associations are bolded and italicized